Sarborg Limited Raises $10 Million Seed

Sarborg Limited, based in Wilmington, Delaware, a company specializing in AI-driven agentic software for drug repurposing and decision optimization, has successfully raised $10 million in a Seed funding round. This latest investment brings the company's total funding to $10 million to support its proprietary technology and expand its operational capabilities.

Investors

This funding round was led by Corvus Capital.

Sarborg Limited Use of Funds

The company plans to use the new capital to advance its proprietary AI agents focused on drug repurposing, target identification, and clinical trial optimization. Additionally, funds will be allocated to develop new pharmaceutical intellectual property, grow the internal pipeline of pharmaceutical assets for monetization, and expand the company's client base and revenue-generating service business.

About Sarborg Limited

Founded in 2024, Sarborg Limited integrates proprietary AI agents, mathematical algorithms, and cybernetics to optimize decision-making processes. The company primarily utilizes machine learning and algorithmic strategies to evaluate drug repurposing by matching drug and disease signatures, aiming to improve the probability of success in clinical trials. The company is currently scaling its technology for applications beyond the pharmaceutical sector.

Funding Details

Company Website: https://sarborg.com

Company: Sarborg Limited
Raised: $10 Million
Round: Seed
Funding Date: August 27, 2025
Lead Investor: Corvus Capital
Company Website: www.sarborg.com
Software Category: Artificial Intelligence
Source: https://www.globenewswire.com/news-release/2025/08/27/3140019/0/en/sarborg-limited-closes-10-million-seed-round-to-expand-proprietary-agentic-approach.html